Starling Oncology, Inc.
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
STLN$4.34+8.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| PageNumber(s) | |
|---|---|
| Consolidated Financial Statements | 61 |
| Report of Independent Registered Public Accounting Firm (BDO USA, P.C.; Costa Mesa, California; PCAOB ID#243) | 62 |
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | 63 |
| Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 | 65 |
| Consolidated Statements of Stockholders' Equity for the years ended December 31, 2024, and 2023 | 66 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | 67 |
| Notes to the Consolidated Financial Statements | 69 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.